Clinical Trial Update: Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating retifanlimab and epacadostat with radiation and bevacizumab in recurrent gliomas has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Epacadostat (epacadostat)
• Retifanlimab (retifanlimab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Glioma, Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2025-08-07